Lung Damage in Rheumatoid Arthritis—A Retrospective Study
暂无分享,去创建一个
C. Codreanu | L. Enache | C. Mogoșan | C. Popescu | M. Agache | G. Dinache
[1] G. Tonini,et al. A COPD Patient Who Developed Pulmonary Fibrosis Following COVID-19: A Case Study , 2021, Global Journal of Respiratory Care.
[2] V. Cottin,et al. Spectrum of Fibrotic Lung Diseases. , 2020, The New England journal of medicine.
[3] M. Kreuter,et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. , 2020, The Lancet. Respiratory medicine.
[4] S. Raoof,et al. An Algorithmic Approach to the Interpretation of Diffuse Lung Disease on Chest CT Imaging: A Theory of Almost Everything. , 2020 .
[5] S. Raoof,et al. How I Do It: An Algorithmic Approach to the Interpretation of Diffuse Lung Disease on Chest CT Imaging. , 2019, Chest.
[6] V. Cottin. Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases , 2019, European Respiratory Review.
[7] Jonathan H. Chung,et al. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases , 2019, Annals of the American Thoracic Society.
[8] Anand Devaraj,et al. Role of imaging in progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.
[9] P. Brillet,et al. The place of high-resolution computed tomography imaging in the investigation of interstitial lung disease , 2018, Expert review of respiratory medicine.
[10] D. Lederer,et al. Idiopathic Pulmonary Fibrosis. , 2018, The New England journal of medicine.
[11] K. Brown,et al. What's in a name? That which we call IPF, by any other name would act the same , 2018, European Respiratory Journal.
[12] C. Schade-Brittinger,et al. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial , 2017, BMC Pulmonary Medicine.
[13] Yaning Wang,et al. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis , 2017, Annals of the American Thoracic Society.
[14] H. Collard,et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease , 2017, BMJ Open Respiratory Research.
[15] R. Takei,et al. Serological and morphological prognostic factors in patients with interstitial pneumonia with autoimmune features , 2017, BMC Pulmonary Medicine.
[16] P. Brillet,et al. When Deep Blue first defeated Kasparov: is a machine stronger than a radiologist at predicting prognosis in idiopathic pulmonary fibrosis? , 2017, European Respiratory Journal.
[17] Shandra L. Protzko,et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. , 2015, American journal of respiratory and critical care medicine.
[18] H. Hatabu,et al. Biomarkers of Rheumatoid Arthritis–Associated Interstitial Lung Disease , 2015, Arthritis & rheumatology.
[19] Thierry Troosters,et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease , 2014, European Respiratory Journal.
[20] G. Tonini,et al. Lung Nodule and Functional Changes in Smokers After Smoking Cessation Short-Term Treatment , 2014, Cancer investigation.
[21] V. Holers,et al. When and where does inflammation begin in rheumatoid arthritis? , 2014, Current opinion in rheumatology.
[22] J. Norris,et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. , 2013, Arthritis and rheumatism.
[23] Shandra L. Protzko,et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.
[24] R. Winchester,et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease , 2013, Annals of the rheumatic diseases.
[25] Lisa Harlow,et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. , 2013, Arthritis and rheumatism.
[26] Takeshi Johkoh,et al. American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .
[27] A. Silman,et al. UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .
[28] A. Silman,et al. Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .
[29] A. Nicholson,et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia , 2009, European Respiratory Journal.
[30] M. Sugimoto,et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. , 2008, The Journal of rheumatology.
[31] L. Klareskog,et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells , 2008, Annals of the rheumatic diseases.
[32] E. Kulinskaya,et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. , 2006, Rheumatology.
[33] J. Hankinson,et al. Standardisation of spirometry , 2005, European Respiratory Journal.
[34] M. Danacı,et al. Pulmonary involvement in rheumatoid arthritis , 2005, Rheumatology International.
[35] J. Seo,et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. , 2005, Chest.
[36] P. Laippala,et al. Death rates and causes of death in patients with rheumatoid arthritis: a population‐based study , 2004, Scandinavian journal of rheumatology.
[37] D. Symmons,et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. , 2003, The Journal of rheumatology.
[38] J. Dawson,et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests , 2001, Thorax.
[39] C. Turesson,et al. Extra-articular rheumatoid arthritis: prevalence and mortality. , 1999, Rheumatology.
[40] M. Remy-Jardin,et al. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. , 1998, American journal of respiratory and critical care medicine.
[41] Y. Sugiyama,et al. Diffuse panbronchiolitis and rheumatoid arthritis: a possible correlation with HLA-B54. , 1994, Internal medicine.
[42] R. Cooper,et al. HLA associations in subjects with rheumatoid arthritis and bronchiectasis but not with other pulmonary complications of rheumatoid disease. , 1993, British journal of rheumatology.
[43] P. Charles,et al. HLA-B40: a marker for susceptibility to lung disease in rheumatoid arthritis. , 1991, Disease markers.
[44] M. Hochberg,et al. HLA-DR4 and pulmonary dysfunction in rheumatoid arthritis , 1987 .
[45] S. Gabriel,et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. , 2003, Arthritis and rheumatism.
[46] S. Gabriel,et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.
[47] M. Obana,et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. , 1994, The Journal of rheumatology.